These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

561 related items for PubMed ID: 24814090

  • 21. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    Sands BE, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S, VARSITY Study Group.
    N Engl J Med; 2019 Sep 26; 381(13):1215-1226. PubMed ID: 31553834
    [Abstract] [Full Text] [Related]

  • 22. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
    Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK.
    N Engl J Med; 2005 Jun 16; 352(24):2499-507. PubMed ID: 15958805
    [Abstract] [Full Text] [Related]

  • 23. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB.
    Gastroenterology; 2012 Feb 16; 142(2):257-65.e1-3. PubMed ID: 22062358
    [Abstract] [Full Text] [Related]

  • 24. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T, AJM300 Study Group.
    Lancet Gastroenterol Hepatol; 2022 Jul 16; 7(7):648-657. PubMed ID: 35366419
    [Abstract] [Full Text] [Related]

  • 25. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
    Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS.
    Gut; 2006 Nov 16; 55(11):1568-74. PubMed ID: 16603634
    [Abstract] [Full Text] [Related]

  • 26. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.
    Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, Xuan W, Lin E, Mitchell HM, Borody TJ.
    Lancet; 2017 Mar 25; 389(10075):1218-1228. PubMed ID: 28214091
    [Abstract] [Full Text] [Related]

  • 27. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P, PURSUIT-Maintenance Study Group.
    Gastroenterology; 2014 Jan 25; 146(1):96-109.e1. PubMed ID: 23770005
    [Abstract] [Full Text] [Related]

  • 28. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
    Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG.
    Lancet; 2023 Apr 08; 401(10383):1159-1171. PubMed ID: 36871574
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
    Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS.
    Lancet Neurol; 2014 Sep 08; 13(9):885-92. PubMed ID: 25127173
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis.
    Wei X, Gibiansky L, Wang Y, Fuh F, Erickson R, O'Byrne S, Tang MT.
    J Clin Pharmacol; 2018 Mar 08; 58(3):386-398. PubMed ID: 29178491
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
    Vermeire S, Sands BE, Tilg H, Tulassay Z, Kempinski R, Danese S, Bunganič I, Nitcheu J, Santo J, Scherrer D, Biguenet S, Ehrlich HJ, Steens JM, Gineste P, Sandborn WJ.
    Lancet Gastroenterol Hepatol; 2022 Nov 08; 7(11):1024-1035. PubMed ID: 36075249
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.